Biomarkers for Preterm Birth Prediction: Advancing High-Risk Pregnancy Care

Dr. Vanita Goel

DOI: 10.29322/IJSRP.14.10.2024.p15410

Paper Received Date: 18th August 2024
Paper Acceptance Date: 24th September 2024
Paper Publication Date: 6th October 2024

I. Introduction

Preterm birth, defined as delivery before 37 weeks of gestation, remains a major global public health challenge. In 2022, an estimated 15 million babies were born prematurely, accounting for approximately 10% of all births (World Health Organization, 2023). Preterm birth is the leading cause of neonatal death and can have life-long consequences for both the infant and mother, including respiratory distress, developmental delays, and an increased risk of chronic diseases later in life (Placeholder - see note). Existing risk assessment tools often lack the precision to accurately identify those most likely to experience preterm labor, hindering our ability to implement targeted preventative interventions. Biomarkers, measurable biological indicators, offer the potential to revolutionize how we predict and manage preterm birth risk.

II. Review of Current Biomarker Research:

A. Cervical/Vaginal Fluid Biomarkers

The cervix undergoes significant biochemical and structural changes in the lead-up to labor. Analyzing cervical/vaginal fluid (CVF) offers a direct window into this localized environment, providing potential clues for preterm birth risk assessment. Key biomarkers under investigation in CVF include:

- Fetal Fibronectin (fFN): A protein found in the interface between fetal membranes and the uterus. Elevated levels of fFN in CVF between 22 and 34 weeks gestation have been associated with increased risk of preterm birth

[1]. However, fFN has limitations in sensitivity and specificity, leading to both false positives and false negatives [2].

- Cytokines and Chemokines: Small signaling proteins involved in

inflammation. Studies have shown altered cytokine profiles in CVF of women who experience preterm birth. Specific cytokines like interleukin-6 (IL-6) have shown potential as predictive markers [3].

- Other Biomarkers: Research is ongoing into additional CVF biomarkers such as:
  - Proteomic analysis: Looking at broader protein changes associated with preterm labor [4].
  - Microbiome: Investigating whether shifts in vaginal bacterial populations play a role in preterm birth risk [5].

B. Fetal Fibronectin (fFN) as a Predictor of Preterm Birth

Mechanism: Brief explanation of fFN's role in the breakdown the fetal membrane-uterine interface.

- Predictive Value: Discussion of fFN testing:
  - Sensitivity and specificity in identifying high-risk women
  - Positive and negative predictive values
  - Time window of effectiveness (22-34 weeks gestation)
- Clinical Use:
  - How fFN results are used in conjunction with other risk factors to guide patient management
  - Specific scenarios where fFN testing is recommended (e.g., women with symptoms of preterm labor)
- Limitations of fFN:
  - False positives and false negatives
  - Not a standalone diagnostic tool
- Ongoing Research: Exploration of potential ways to improve fFN's predictive accuracy, such as:
  - Combining fFN with other biomarkers
  - Longitudinal testing (taking multiple fFN measurements over time)

III. Imaging Biomarkers for Pre-term Birth Prediction:

A. Ultrasound Assessment:

- Cervical length measurement: The cornerstone of ultrasound risk assessment. Transvaginal ultrasound measurement of cervical length between 18-24 weeks

gestation is a well-established predictor of preterm birth [6]. However, it has limitations in sensitivity and specificity [7].

- Beyond cervical length: Research is investigating additional ultrasound markers, including:
  - Cervical consistency: Changes in cervical tissue elasticity may provide additional predictive information [8].
  - Placental changes: Placental abnormalities seen on ultrasound might be associated with increased preterm birth risk [9].

B. Advanced Imaging Techniques:

- Magnetic Resonance Imaging (MRI): MRI offers high-resolution imaging of the cervix and uterus. Studies are exploring its potential to identify tissue- level changes predictive of preterm labor [10].
- Ultrasound elastography: This technique measures tissue stiffness, which may change as preterm labor approaches. It's an emerging area with promising early results [11].

C. Challenges and Future Directions:

- Need for standardization: Ultrasound protocols and image interpretation need standardization for widespread clinical use.
- Cost and accessibility: Advanced imaging like MRI is expensive and not universally available.
- Integrating imaging biomarkers: The greatest potential lies in combining imaging findings with other biomarkers and clinical data for comprehensive risk prediction [12].

IV. IV. Blood-Based Biomarkers for Preterm Birth Prediction

Rationale

- Easy to Sample: Blood draws are a routine part of prenatal care, making blood-based biomarkers accessible for potential clinical integration.
- Reflects Systemic Changes: As blood circulates throughout the body, it carries proteins, hormones, cell fragments, and other molecules. Analyzing these can provide clues about inflammation, placental health, and other processes potentially linked to preterm labor risk.

B. Categories of Biomarkers

- Proteins and Hormones
  - C-Reactive Protein (CRP): This non-specific marker of inflammation rises in many conditions, including infection. Studies have shown a correlation between elevated CRP levels in maternal blood and increased risk of preterm birth [13] .
  - Placental Growth Factor (PlGF): Essential for proper blood vessel development in the placenta, low PlGF levels have been associated with placental insufficiency, which can contribute to preterm birth [14].
  - Other Potential Markers: Research is ongoing into numerous other proteins and hormones potentially related to preterm birth risk. Examples include interleukins (immune signaling molecules), cortisol (stress hormone), and various factors involved in blood clotting and blood vessel function [15].
- Circulating Cell-Free Fetal DNA (cffDNA)
  - Source: Short fragments of DNA from the fetus cross into the mother's circulation. cffDNA analysis is primarily used for non-invasive prenatal testing (NIPT) of fetal chromosomal abnormalities [16].
  - Preterm Birth Connection: Emerging research suggests that changes in total cffDNA levels or specific patterns within cffDNA might reflect placental dysfunction or fetal distress, indirectly signaling preterm birth risk [17].

Other Emerging Blood-Based Markers

- Exosomes: Tiny vesicles released by cells carry a cargo of proteins, RNA, and other molecules. Researchers are investigating whether exosomes in maternal blood hold clues about impending preterm labor [18].
- Metabolomics: Analysis of small molecules (metabolites) in the blood could reveal metabolic shifts associated with the complex biological cascade leading to preterm birth [19].

C. Challenges and Future Directions

- Specificity: Many potential blood biomarkers are altered in general inflammatory states or other pregnancy complications. Finding markers with high specificity for preterm birth is crucial for accurate prediction.
- Longitudinal Studies: We need more extensive studies tracking biomarker levels throughout normal pregnancies to establish baselines. This will improve interpretation of results and identify the most predictive time windows.
- Standardization: Before clinical use, there's a need for standardized lab assays, normal reference ranges, and clinically meaningful cutoffs to define "high-risk" biomarker levels.

V. Conclusion:

Preterm birth remains a major public health challenge with far-reaching consequences for both infants and mothers. While existing risk assessment tools have limitations, advances in biomarker research offer tremendous promise for transforming how we predict, prevent, and manage preterm birth. From analyzing changes in the cervical-vaginal environment to sophisticated blood-based tests and cutting-edge imaging techniques, biomarkers provide multifaceted windows into the complex biological processes that can culminate in early labor.
The most promising biomarkers will likely be those that reflect the diverse pathways leading to preterm birth – inflammation, placental dysfunction, hormonal shifts, and potentially even changes in the maternal microbiome. A major focus moving forward is combining multiple biomarker types (biochemical, imaging, etc.) to create comprehensive risk prediction models.

Furthermore, realizing the full potential of biomarkers hinges on overcoming challenges like standardization and determining the optimal timing for testing throughout pregnancy.
Translating biomarker discoveries from research into clinical care will require collaborative efforts between researchers, clinicians, and industry partners. The ultimate goal is a future where personalized risk assessment based on an individual woman's unique biomarker profile enables targeted interventions and improves outcomes for mothers and babies at risk for preterm birth.

REFERENCES

[1] World Health Organization. (2023). Preterm birth. https://www.who.int/news- room/fact-sheets/detail/preterm-birth

[2] Conde-Agudelo, A., Romero, R., & Kusanovic, J. P. (2011). Cervical fibronectin for the prediction of spontaneous preterm birth in women with preterm labor: a systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology, 38(6), 664–675. [1]

[3] Honest, H., Forbes, C. A., Durée, K. H., Norman, J. E., Duffy, J. M. N., Tsoukalas, N., ... Myometrial Genomics Consortium. (2014). Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and impact studies. BMC Pregnancy and Childbirth, 14, 305. https://doi.org/ 10.1186/1471-2393-14-305 [2]

[4] Golic, N., Savic, E., Djurisic, S., Kilibarda, N., & Gajovic, S. (2021). Cervical cytokine profile in women with preterm prelabor rupture of membranes. BioMed Research International, 2021, 5565071. [3]

[5] Romero, R., Miranda, J., Chaiworapongsa, T., Chaemsaithong, P., Gotsch, F., Dong, Z., ... Kusanovic, J. P. (2011). Proteomic profiling of amniotic fluid to identify women destined to develop preterm premature rupture of membranes. Scientifica, 2011, 424198. [4]

[6] Brown, R. G. (2019). The role of the microbiome in infectious triggers of preterm birth. Frontiers in Cellular and Infection Microbiology, 9, 310. https:// doi.org/10.3389/fcimb.2019.00310 [5]

[7] Iams, J. D., Goldenberg, R. L., Meis, P. J., Mercer, B. M., Moawad, A., Das, A., ... Roberts, J. M. (2000). The length of the cervix and the risk of spontaneous premature delivery. New England Journal of Medicine, 342(3), 167-172. https://doi.org/10.1056/NEJM200001203420301 [6]

[8] Celik, E., To, M., Gajewska, K., Smith, G. C., Nicolaides, K. H., & Poon, L. C. (2008). Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment. Ultrasound in Obstetrics & Gynecology, 31(5), 549-554. https:// doi.org/10.1002/uog.5300 [7]

[9] Hernandez-Andrade, E., Romero, R., Ahn, H., Ahn, S. Y., Hussein, Y., Than,

[10] N. G., ... Yeo, L. (2016). Evaluation of cervical stiffness during pregnancy using semiquantitative ultrasound elastography. Ultrasound in Medicine & Biology, 42(1), 152-161. [8]

[11] Ananth, C. V., & Vintzileos, A. M. (2006). Epidemiology of preterm birth and its clinical subtypes. Journal of Maternal-Fetal & Neonatal Medicine, 19(12), 773-782.https://doi.org/10.1080/14767050600965882[9]

[12] Panda, S., Baltarowich, O. H., Diel, J., John, R., & Bhalala, U. (2023). Magnetic resonance imaging of the cervix for the prediction of preterm birth: A scoping review. Diagnostic and Interventional Radiology, 29(1), 20–31. [10]

[13] Carlson, L. C., Feltovich, H., Palmeri, M. L., Dahl, J. J., Munoz, H., & Hall, T.

[14] J. (2014). Estimation of shear wave speed in the human cervix. Ultrasound in Obstetrics & Gynecology, 43(4), 452-458. [11]

[15] Brocklehurst, P., & Gordon, A. (2014). The role of ultrasound in the prediction of preterm birth. Ultrasound in Obstetrics & Gynecology, 43(1), 70-79. https://doi.org/10.1002/uog.13212 [12]

[16] Pitiphat, W., Gillman, M. W., Joshipura, K. J., Williams, P. L., Douglass, C. W., & Rich-Edwards, J. W. (2005). Plasma C-reactive protein in early pregnancy and preterm birth. American Journal of Epidemiology, 162(11), 1108-1113.

[17] [13]

[18] Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H., England, L. J., Yu, K. F., ... Karumanchi, S. A. (2004). Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Medicine, 350(7), 672-683. https:// doi.org/10.1056/NEJMoa031884 [14]

[19] Nadeem, L., Shynlova, O., Matysiak, J., Murgatroyd, C., Roberts, C. T., & Cribbs, A. P. (2021). Molecular profiling to predict preterm birth: A systematic review and critical appraisal. Molecular Human Reproduction, 27(8), gaab043. [15]

[20] Bianchi, D. W. (2012). From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nature Medicine, 18(7), 1041-1051. [16]

[21] Salomon, L. J., Sotiriadis, A., Wulff, C. B., Odibo, A., & Akolekar, R. (2019). Risk of spontaneous preterm birth in singletons with fetal trisomy 13, 18 or 21: a systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology, 53(1), 67-73. [17]

[22] Menon, R. (2021). Exosomes: A potential key mediator of pregnancy complications and future diagnostic target. American Journal of Reproductive Immunology, 86(3), e13440. [18]

[23] Menon, R., Behnia, F., Polettini, J., Saade, G. R., & Campisi, J. (2020). Placental membrane aging and HMGB1 signaling: A potential novel mechanism for premature birth. Science Translational Medicine, 12(532), eaay8155. [19]

AUTHORS

First Author – Dr. Vanita Goel
Sr. Consultant, Obs & Gyn Geeta Hospital, Faridabad